Home / Health / Experimental Eye Drug Fails to Meet Trial Goal
Experimental Eye Drug Fails to Meet Trial Goal
17 Aug
Summary
- Experimental eye drug Duravyu failed its main clinical trial goal.
- The drug was tested against a standard treatment for vision loss.
- A small patient group skewed results, obscuring overall drug efficacy.
On Monday, EyePoint announced that its experimental eye medication, Duravyu, did not achieve its primary endpoint in a crucial late-stage clinical trial. This drug was under investigation as a potential treatment for wet age-related macular degeneration, a leading contributor to vision impairment.
The trial aimed to demonstrate improved vision compared to a standard therapy, aflibercept. However, EyePoint reported that the study's main target was not met. The company indicated that the overall results were influenced by a specific, small group of participants, which obscured the drug's performance across the entire study population.
Following this announcement, trading of EyePoint shares was suspended in pre-market activity. The trial's outcome represents a setback for the company's development pipeline.
